Efficacy and safety of Ruxolitinib in steroid-refractory/dependent chronic graft-versus-host disease: Real-world Data and Challenges.

[1]  F. Locatelli,et al.  Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. , 2021, The New England journal of medicine.

[2]  S. Bhatia,et al.  High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group , 2021, Blood Cancer Journal.

[3]  He Huang,et al.  Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation , 2021, JAMA network open.

[4]  J. Mascarenhas,et al.  Novel therapeutics in myeloproliferative neoplasms , 2020, Journal of Hematology & Oncology.

[5]  F. Locatelli,et al.  Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study , 2020 .

[6]  M. Mohty,et al.  Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. , 2020, The New England journal of medicine.

[7]  M. Arbushites,et al.  Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label, phase 2 trial. , 2020, Blood.

[8]  E. Surkova,et al.  Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults , 2020, Bone Marrow Transplantation.

[9]  J. Sierra,et al.  Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study , 2019, Bone Marrow Transplantation.

[10]  P. Hari,et al.  Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  N. Blijlevens,et al.  Corticosteroid replacement by ruxolitinib in patients with acute GVHD experiencing severe steroid-induced side effects , 2019, Bone Marrow Transplantation.

[12]  J. Dipersio,et al.  Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease , 2018, Bone Marrow Transplantation.

[13]  A. Bergeron,et al.  Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Clinics in chest medicine.

[14]  H. Deeg,et al.  Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment , 2016 .

[15]  Y. Mori,et al.  Ruxolitinib treatment for GvHD in patients with myelofibrosis , 2016, Bone Marrow Transplantation.

[16]  C. Lengerke,et al.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.

[17]  Daniel Wolff,et al.  Measuring Therapeutic Response in Chronic Graft-versus-host-disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus- Host Disease: Iv. Response Criteria Working Group Report , 2022 .

[18]  S. Held,et al.  The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. , 2013, Blood.

[19]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  M. Mohty,et al.  Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update , 2011, Blood cancer journal.

[21]  K. Baird,et al.  Chronic graft versus host disease , 2006, Current opinion in hematology.

[22]  S. Chevret,et al.  A Grading System Based on Severity of Infection to Predict Mortality in Allogeneic Stem Cell Transplant Recipients , 2006, Transplantation.

[23]  T. Luft,et al.  Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  M. Mohty,et al.  Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.